Recombinant Human IL-28A/IFN-lambda 2 Protein

Product Discontinued

Recombinant Human IL-28A/IFN-lambda 2 Protein Summary

• Description: Recombinant bioactive protein for Human IL28A
  
  

  Source:E. coli
  Amino Acid Sequence:(Q8IZJ0)

• Preparation Method: Determined to be >85% pure by SDS-PAGE
• Source: E. coli
• Protein/Peptide Type: Recombinant Protein
• Gene: IFNL2
• Purity: >85%, by SDS-PAGE
• Endotoxin Note: <0.1 ng/ug

Applications/Dilutions

• Dilutions:
  • SDS-Page
• Theoretical MW: 19.6 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.

Packaging, Storage & Formulations

• Storage: Store at -20 to -80C. Avoid freeze-thaw cycles.
• Buffer: Sterile filtered and lyophilized with no additives
• Concentration: Lyoph
• Purity: >85%, by SDS-PAGE
• Reconstitution Instructions: Reconstitute in sterile dH2O not less than 100 g/ml. This solution can then be diluted into other aqueous buffers

Alternate Names for Recombinant Human IL-28A/IFN-lambda 2 Protein

• IFN-lambda 2/IL-28A
• interleukin-28A
• IFN-lambda 2
• IL28A
• IL-28A
• interferon, lambda 2

Background

IL-28A is distantly related to type I interferons and the IL-10 family. Expression of IL-28A is induced by viral infection which interacts with a heterodimeric class II cytokine receptor that consists of interleukin 10 receptor, Beta (IL10RB) and interleukin 28 receptoralpha. IL-28A exhibits common features with type I IFNs such as antiviral activity, antiproliferative activity and in vivo antitumour activity. IL-28A acts similarly to IFNs, but is less effective generally and has activity in a more limited range of cell lines. IL-28A induces ELR(-) CXC chemokine mRNA in human peripheral blood mononuclear cells, in an IFN-gamma-independent manner. IL-28A produced in response to viral infection, activates both monocytes and macrophages producing a restricted panel of cytokines and therefore is an important factor in activating innate immune responses at the site of viral infection. Recombinant human IL-28A produced in E.Coli is a single, non-glycosylated, polypeptide chain containing 175 amino acids and having a molecular mass of 19.6 kDa.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Peptides and proteins are guaranteed for 3 months from date of receipt.

Bioinformatics

• Gene Symbol: IFNL2